Redx Pharma inks cancer research deal with French group
FAST-growing North West company Redx Pharma has agreed a partnership deal with French group Pierre Fabre Laboratories to explore a skin cancer treatment.
The exclusive deal will see Redx and Pierre Fabre Laboratories (IRPF), the second-biggest pharma company in France, work together on the evaluation and development project.
Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.
The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray said the deal is “a highly significant milestone”.
Work will be carried-out in Liverpool by subsdiary Redx Oncology.
Dr Murray said: “The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits. We look forward to benefitting from Pierre Fabre’s outstanding capabilities in this area and developing a long and successful partnership.”
He added: “It’s the most important deal we have completed to date and our first international research and development collaboration. Pierre Fabre has world class expertise in cancer and dermatology. The deal validates our commercial model of providing pipeline of exciting new drugs to the pharmaceutical industry. Building on this real breakthrough for our business we have a number of further deals under negotiation with other partners.”
Christian Bailly, head of research at Pierre Fabre Pharmaceuticals, added: “Combining our capabilities with Redx researchers will accelerate our drug discovery process.”
